Angion Biomedica (ANGN)

Angion Biomedica (ANGN) Stock Price & Analysis


ANGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.46 - $2.04
Previous Close$0.95
Average Volume (3M)70.51K
Market Cap
Enterprise Value-$301.00K
Total Cash (Recent Filing)$29.20M
Total Debt (Recent Filing)$297.00K
Price to Earnings (P/E)-1.0
Aug 10, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding30,113,703
10 Day Avg. Volume162,209
30 Day Avg. Volume70,506
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)0.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.46
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.01
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Angion Biomedica’s price range in the past 12 months?
Angion Biomedica lowest stock price was $0.46 and its highest was $2.04 in the past 12 months.
    What is Angion Biomedica’s market cap?
    Currently, no data Available
    When is Angion Biomedica’s upcoming earnings report date?
    Angion Biomedica’s upcoming earnings report date is Aug 10, 2023 which is in 74 days.
      How were Angion Biomedica’s earnings last quarter?
      Angion Biomedica released its earnings results on May 15, 2023. The company reported -$0.151 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.151.
        Is Angion Biomedica overvalued?
        According to Wall Street analysts Angion Biomedica’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Angion Biomedica pay dividends?
          Angion Biomedica does not currently pay dividends.
          What is Angion Biomedica’s EPS estimate?
          Angion Biomedica’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Angion Biomedica have?
          Angion Biomedica has 30,113,703 shares outstanding.
            What happened to Angion Biomedica’s price movement after its last earnings report?
            Angion Biomedica reported an EPS of -$0.151 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.282%.
              Which hedge fund is a major shareholder of Angion Biomedica?
              Currently, no hedge funds are holding shares in ANGN


              Angion Biomedica Stock Smart Score

              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              Angion Biomedica

              Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.


              Top 5 ETFs holding ANGN

              Currently, no data available
              Please return soon. This page is being updated.
              Up to five ETFs with an Outperform Smart Score that hold ANGN. The ETFs are listed according to market value of ANGN within the ETF


              Forecast EPS vs Actual EPS

              Similar Stocks
              Price & Change
              Satsuma Pharmaceuticals
              Lowell Farms
              Zynerba Pharmaceuticals
              Real Brands

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis